NTLA

NTLA R&D to Revenue

574.63%Fiscal year

Period ending:

NTLA FY R&D/Revenue%
NTLA FY R&D/Revenue1343.29%-143.92%
2014-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.

NTLA r&d to revenue history

R&D spending as percentage of revenue. The available annual fiscal periods series contains 12 observations from Dec 31, 2014 to Dec 31, 2025.

Intellia Therapeutics Inc R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
574.6346%
805.6931%
1,199.3632%
805.7769%
695.2682%
259.351%
251.5208%
292.814%
259.0152%
193.2156%
184.8114%
0%

Compare r&d to revenue

All NTLA financial metrics · NTLA stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.